VKTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Viking Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$25.05−0.12 (-0.48%)
Close on Oct 19, 2026
- Market cap
- $2.91B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$8.48 (−25.30%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Viking Therapeutics, Inc. reported revenue of $0 for the twelve months to Jun 30, 2026.
Revenue
$0
TTM Q2 2026
Operating income
-$560.02M
TTM Q2 2026
EPS, diluted
-$4.66
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $2.91B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 7.13
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $0
- Net income
- -$534.80M
- EPS, diluted
- -$4.66
- Book value per share
- $3.51
- Diluted shares
- 116M
Thirteen years at a glance
Fiscal years 2013 to 2025 and trailing twelve months, USD
Revenue
$0
Operating income
-$560.02M
Net income
-$534.80M
EPS, diluted
-$4.66
Reported periodTrailing twelve months